Free Trial
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

Soleno Therapeutics logo
$54.99 +0.16 (+0.29%)
(As of 11/21/2024 ET)

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Key Stats

Today's Range
$53.41
$55.97
50-Day Range
$46.88
$59.18
52-Week Range
$26.38
$59.75
Volume
264,094 shs
Average Volume
468,477 shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.83
Consensus Rating
Buy

Company Overview

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
80th Percentile Overall Score

SLNO MarketRank™: 

Soleno Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 219th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Soleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Soleno Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Soleno Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($3.76) to ($2.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Soleno Therapeutics is -16.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Soleno Therapeutics is -16.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Soleno Therapeutics has a P/B Ratio of 8.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Soleno Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    20.09% of the float of Soleno Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Soleno Therapeutics has a short interest ratio ("days to cover") of 9.8.
  • Change versus previous month

    Short interest in Soleno Therapeutics has recently increased by 8.06%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Soleno Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Soleno Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.09% of the float of Soleno Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Soleno Therapeutics has a short interest ratio ("days to cover") of 9.8.
  • Change versus previous month

    Short interest in Soleno Therapeutics has recently increased by 8.06%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Soleno Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    11 people have searched for SLNO on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,970,517.00 in company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Soleno Therapeutics' insider trading history.
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Stock News Headlines

Soleno Therapeutics Reports Q3 Progress and Financials
Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
Cantor Fitzgerald Remains a Buy on Soleno Therapeutics (SLNO)
See More Headlines

SLNO Stock Analysis - Frequently Asked Questions

Soleno Therapeutics' stock was trading at $40.25 on January 1st, 2024. Since then, SLNO stock has increased by 36.6% and is now trading at $54.9944.
View the best growth stocks for 2024 here
.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($1.83) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $1.22.

Soleno Therapeutics shares reverse split on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Top institutional shareholders of Soleno Therapeutics include Janus Henderson Group PLC (9.46%), State Street Corp (2.65%), Vestal Point Capital LP (1.67%) and Wellington Management Group LLP (1.58%). Insiders that own company stock include Vivo Opportunity, Llc, Perceptive Advisors Llc, Bhatnagar Anish, Jack W Schuler, James H Mackaness and Kristen Yen.
View institutional ownership trends
.

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
11/06/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/05/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:SLNO
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.83
High Stock Price Target
$93.00
Low Stock Price Target
$67.00
Potential Upside/Downside
+36.1%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-38,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.14 per share

Miscellaneous

Free Float
37,814,000
Market Cap
$2.37 billion
Optionable
Optionable
Beta
-1.44

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:SLNO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners